ILCA 2021 will be the premier forum for clinical, translational and basic researchers and physicians, as well as allied professionals across liver cancer-related disciplines to share best practices and findings and advance research in the pathogenesis, prevention, and treatment of liver cancer.

Reserve your seat before 30 May and save up to 125€ with our early bird discounted rates!


Attend #ILCA21 with the Educational Grant

Bristol Myers Squibb offers 250 free registrations to students and trainees in the liver cancer field


Clinical Science Symposium: The future of combination therapies in HCC

Hear about expectations from triple therapies (rationale, prospects and trials), and learn more practical aspects with current issues with patients.

Robin Kate Kelley
Associate Professor of Clinical Medicine in the Department of Medicine at the University of California, (UCSF)
San Francisco, USA

David James Pinato
Clinical Senior Lecturer in Medical Oncology at the Imperial College London
London, UK

Josep M. Llovet
Founder and Director of the Liver Cancer Program and Full Professor of Medicine at the Mount Sinai School of Medicine, New York University (USA), and Professor of Research-ICREA in the BCLC Group, Liver Unit, IDIBAPS-Hospital Clínic, University of Barcelona